Shine-On Biomedical Co., Ltd.(TW:6926)
NT$60.000.00 (0.00%)
TW:6926
Shine-On Biomedical Co., Ltd. financials statements
NT$60.00
At close:0.00 (0.00%)
Shine-On Biomedical Co., Ltd. (6926) Ratios
Shine-On Biomedical Co., Ltd. Ratios
TW:6926's free cash flow for Q2 2026 was NT$-112.67M. For the 2026 fiscal year, TW:6926's free cash flow was decreased by NT$-41.00K and operating cash flow was NT$-112.62M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 21.48 | 25.92 | 49.61 | 369.30 | 330.89 |
| Quick Ratio | 21.48 | 25.92 | 49.61 | 369.30 | 330.89 |
| Cash Ratio | 1.13 | 1.10 | 4.39 | 117.90 | 301.20 |
| Solvency Ratio | -2.48 | -2.76 | -1.52 | -4.33 | -1.83 |
| Operating Cash Flow Ratio | -2.64 | -2.25 | -1.16 | -6.84 | -2.32 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | -34.10 |
| Net Current Asset Value | NT$ 891.40M | NT$ 1.01B | NT$ 1.13B | NT$ 1.16B | NT$ 902.05M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.05 | 1.04 | 1.02 | 1.00 | 1.00 |
| Debt Service Coverage Ratio | -4566.56 | -4487.50 | -2710.38 | -688.19 | -38.50 |
| Interest Coverage Ratio | -4648.07 | -5233.58 | -4821.77 | -838.12 | -539.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.03 | 0.05 | 0.01 | 0.03 | 0.06 |
| Net Debt to EBITDA | 0.39 | 0.36 | 3.07 | 18.43 | 105.74 |
| Profitability Margins | |||||
| Gross Profit Margin | 93.11% | 0.00% | 70.00% | 0.00% | 0.00% |
| EBIT Margin | -418.33% | 0.00% | -366.68% | 0.00% | 0.00% |
| EBITDA Margin | -411.44% | 0.00% | -346.56% | 0.00% | 0.00% |
| Operating Profit Margin | -418.33% | 0.00% | -658.16% | 0.00% | 0.00% |
| Pretax Profit Margin | -368.06% | 0.00% | -366.82% | 0.00% | 0.00% |
| Net Profit Margin | -367.62% | 0.00% | -390.22% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | -367.62% | 0.00% | -390.22% | 0.00% | 0.00% |
| Net Income Per EBT | 99.88% | 100.25% | 106.38% | 89.58% | 100.00% |
| EBT Per EBIT | 87.98% | 87.15% | 55.73% | 100.12% | 97.76% |
| Return on Assets (ROA) | -11.60% | -11.22% | -3.20% | -1.66% | -0.92% |
| Return on Equity (ROE) | -12.16% | -11.68% | -3.27% | -1.67% | -0.93% |
| Return on Capital Employed (ROCE) | -13.83% | -13.35% | -5.52% | -1.86% | -0.95% |
| Return on Invested Capital (ROIC) | -13.79% | -13.33% | -5.51% | -1.66% | -0.95% |
| Return on Tangible Assets | -11.71% | -11.26% | -3.21% | -1.66% | -0.93% |
| Earnings Yield | -3.16% | -3.51% | -1.13% | -0.69% | -0.25% |
| Efficiency Ratios | |||||
| Receivables Turnover | 10.94 | 0.00 | 0.95 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 1.00 | 0.00 | 3.43 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 21.47 | 0.00 | 6.20 | 0.00 | 0.00 |
| Asset Turnover | 0.03 | 0.00 | 0.01 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.03 | 0.00 | 0.01 | 0.00 | 0.00 |
| Cash Conversion Cycle | 33.37 | 0.00 | 18.24 | 0.00 | -106.41 |
| Days of Sales Outstanding | 33.37 | 0.00 | 383.24 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 365.00 | 0.00 | 106.41 |
| Operating Cycle | 33.37 | 0.00 | 383.24 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.30 | -1.84 | -0.54 | -0.48 | -0.14 |
| Free Cash Flow Per Share | -2.33 | -1.85 | -0.55 | -0.54 | -0.20 |
| Dividend Paid and CapEx Coverage Ratio | -110.33 | -150.41 | -40.60 | -7.80 | -2.15 |
| Capital Expenditure Coverage Ratio | -110.33 | -150.41 | -40.60 | -7.80 | -2.15 |
| Operating Cash Flow Coverage Ratio | -84.62 | -35.21 | -49.96 | -14.29 | -2.38 |
| Operating Cash Flow to Sales Ratio | -3.82 | 0.00 | -2.82 | 0.00 | 0.00 |
| Free Cash Flow Yield | -3.32% | -2.71% | -0.84% | -0.86% | -0.27% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -31.67 | -28.49 | -88.13 | -145.58 | -395.26 |
| Price-to-Sales (P/S) Ratio | 116.20 | 0.00 | 345.63 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 3.84 | 3.33 | 2.90 | 2.42 | 3.76 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -30.11 | -36.84 | -119.52 | -116.34 | -366.82 |
| Price-to-Operating Cash Flow Ratio | -30.38 | -37.09 | -122.47 | -131.25 | -537.73 |
| Price-to-Earnings Growth (PEG) Ratio | 4.21 | -0.13 | -1.18 | -1.15 | 0.00 |
| Enterprise Value Multiple | -27.86 | -28.78 | -96.66 | -122.53 | -332.77 |
| Enterprise Value | 3.44B | 3.35B | 3.19B | 2.47B | 2.59B |
| EV to EBITDA | -27.86 | -28.78 | -96.66 | -122.53 | -332.77 |
| EV to Sales | 114.61 | 0.00 | 334.97 | 0.00 | 0.00 |
| EV to Free Cash Flow | -29.69 | -36.38 | -115.84 | -101.13 | -278.37 |
| EV to Operating Cash Flow | -29.96 | -36.63 | -118.69 | -114.09 | -408.07 |
| Tangible Book Value Per Share | 18.04 | 20.36 | 22.75 | 25.77 | 19.96 |
| Shareholders’ Equity Per Share | 18.22 | 20.43 | 22.82 | 25.85 | 19.99 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | -0.00 | -0.06 | 0.10 | 0.00 |
| Revenue Per Share | 0.60 | 0.00 | 0.19 | 0.00 | 0.00 |
| Net Income Per Share | -2.21 | -2.39 | -0.75 | -0.43 | -0.19 |
| Tax Burden | 1.00 | 1.00 | 1.06 | 0.90 | 1.00 |
| Interest Burden | 0.88 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 4.59 | 0.00 | 5.70 | 0.00 | 0.00 |
| SG&A to Revenue | 0.52 | 0.00 | 1.59 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.04 | 0.77 | 0.77 | 0.99 | 0.75 |
Currency in TWD
